Frågedatum: 1994-11-30
RELIS database 1994; id.nr. 11579, DRUGLINE
www.svelic.se
Utredningen som riktar sig till hälso- och sjukvårdspersonal, har utformats utefter tillgänglig litteratur och resurser vid tidpunkten för utredning. Innehållet i utredningen uppdateras inte. Hälso- och sjukvårdspersonal är ansvarig för hur de använder informationen vid rådgivning eller behandling av patienter.


The question concerns a patient in week nine of pregnancy. During week three of pregnancy, she took



Fråga: The question concerns a patient in week nine of pregnancy. During week three of pregnancy, she took a Greek preparation Ercefuryl for gastrointestinal symptoms. Is there a risk of teratogenic effect?

Sammanfattning: The teratogenic effects of the drug is not known and documentation of this substance is very limited. In general, exposure during the first three to four weeks after conception can be expected to lead to an all-or-none effect with an early sponatenous abortion if the foetus has been harmed.

Svar: Ercefuryl contains nifuroxazide, which is an antibacterial agent that has been given by mouth in a dose of 800 mg daily in the treatment of colitis and diarrhoea (1). It is according to this textbook poorly absorbed from the gastro-intestinal tract. However, no references are given.

A similar question was asked earlier and according to this answer there is no information in the literature indicating a risk of teratogenic effects by nifuroxazide (2). This was confirmed in a follow-up literature search. Nifuroxazide is a nitrofuran derivative similar to nitrofurantoin, which belongs to category A in the Swedish classification system for medicinal product use in pregnancy.

Referenser: